Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

New Polymers and Methods Patent Application

The USPTO has published a new patent application, US20260085336A1, detailing processes for forming pyridinedicarboxylic acid derivatives and copolymers. The application, filed on September 25, 2025, outlines biocatalytic methods and potential uses for these new materials.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Novel Compound Treating Neurodegeneration and Cardiovascular Diseases

The USPTO has published a patent application (US20260085083A1) for a novel compound and pharmaceutical composition developed by SHANDONG RUZHI BIOMEDICINE TECHNOLOGY CO., LTD. The compound is intended for preventing or treating neurodegenerative diseases and cardiovascular/cerebrovascular diseases.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

KDM1A Inhibitors for Disease Treatment Patent Application

The USPTO has published a new patent application (US20260085082A1) from Imago Biosciences, Inc. The application discloses new compounds and compositions for pharmaceutical use, specifically for inhibiting KDM1A and increasing gamma globin gene expression to treat diseases like acute myelogenous leukemia.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici

The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Crystal Form of Aromatic Heterocyclic Compound

The USPTO has published a patent application (US20260085076A1) detailing a new crystal form (I and III) of an aromatic heterocyclic compound. The application also describes a production method and its use in treating diseases related to abnormal JAK-STAT signaling pathways.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Protein Degraders Patent Application

The USPTO has published a new patent application, US20260085075A1, related to protein degraders and their uses. The application was filed on August 19, 2025, by inventors Nello Mainolfi, Nan Ji, Yi Zhang, and Matthew M. Weiss.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a patent application (US20260085074A1) detailing compositions and methods for treating cancer by modulating K-Ras, a frequently mutated oncogene. The application was filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Pyrazolylcarboxamide Compounds for Therapy

The USPTO has published a patent application (US20260085073A1) for pyrazolylcarboxamide compounds and their use in therapy. The application details compounds that inhibit MALT1 and their potential treatment for proliferative, inflammatory, or autoimmune disorders.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Method for Preparing Intermediate of Adrenergic Receptor Agonist

The USPTO has published a patent application detailing a new method for preparing an intermediate of an adrenergic receptor agonist. The method claims to offer improved yield, reduced cost, and milder reaction conditions, making it more favorable for commercial production. The application was filed on December 4, 2025.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Novel Crystalline Form of Amine Compound

The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.

Routine Notice Pharmaceuticals

Showing 12371–12380 of 39,129 changes

1 1236 1237 1238 1239 1240 3913

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.